Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215264 | 0.81 | KDM4E (0.46) | KDM4ECYP2D6OPRK1MAPTLMNA | |
| SCHEMBL6214071 | 0.72 | ALDH1A1 (0.51) | KDM4ECYP2D6OPRK1MAPTLMNA | |
| SCHEMBL20594029 | 0.68 | ALDH1A1 (0.47) | KDM4EMAPTLMNAGAANPC1 | |
| SCHEMBL6984072 | 0.68 | KDM4E (0.43) | KDM4EEPHX2SMN1; SMN2 | |
| SCHEMBL8304517 | 0.68 | CYP2D6 (0.51) | KDM4ECYP2D6OPRK1MAPTLMNA | |
| SCHEMBL2238017 | 0.66 | ALDH1A1 (0.46) | KDM4EMAPTLMNAGAANPC1 | |
| SCHEMBL7465143 | 0.65 | KDM4E (0.51) | KDM4EMAPTEPHX2 | |
| SCHEMBL4599189 | 0.65 | DPP4 (0.38) | GAANPC1RAB9AGRM5 | |
| SCHEMBL5337081 | 0.65 | POLB (0.48) | KDM4EMAPTLMNAGAANPC1 | |
| SCHEMBL28513535 | 0.64 | LTA4H (0.32) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077027-A2 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | KDM4E 2460/4885CYP2D6 786/4885OPRK1 1174/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | KDM4E 2148/4885CYP2D6 477/4885OPRK1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.